Investor Relations
Omni Bio Pharmaceutical, Inc. (OMBP.ob) is an emerging biopharmaceutical company formed to acquire, license, and develop existing novel therapies which have substantial commercialization potential.
Recent Press Releases:
- Dr. Charles A. Dinarello of the University of Colorado and Acting CEO of Omni Bio Pharmaceutical to be Awarded the Paul Ehrlich Prize (10/02/09)
- Omni Bio Pharmaceutical to Present at Accredited Members Fall 2009 Micro Cap/Small Cap Confrence (9/22/09)
- Omni Bio Pharmaceutical Announces Ticker Symbol Change to OMBP (7/20/09)
- Dr. Eli Lewis Joins the Omni Bio Pharmaceutical Scientific Advisory Board (6/24/09)
- Omni Bio Pharmaceutical, Inc. Completes Name Change and Announces Managerial Appointments and Position Changes (6/02/09)
- Dr. Charles A. Dinarello Co-Awarded Largest US Prize in Medical Research, the Albany Medical Center Prize in Medicine and Biomedical Research (4/29/09)
- Across America Financial Services Completes Acquisition of Apro Bio Pharmaceutical Corporation (4/20/09)
Request Information: info@omnibiopharma.com
